JP2004505017A - クロロキンおよび３−（１−（（（４−（（６−メトキシ−８−キノリニル）アミノ）ペンチル）アミノ）−エチリデン）−ジヒドロ−２（３ｈ）フラノンを含有するマラリア治療に使用される組み合わせキット - Google Patents
クロロキンおよび３−（１−（（（４−（（６−メトキシ−８−キノリニル）アミノ）ペンチル）アミノ）−エチリデン）−ジヒドロ−２（３ｈ）フラノンを含有するマラリア治療に使用される組み合わせキット Download PDFInfo
- Publication number
- JP2004505017A JP2004505017A JP2001587559A JP2001587559A JP2004505017A JP 2004505017 A JP2004505017 A JP 2004505017A JP 2001587559 A JP2001587559 A JP 2001587559A JP 2001587559 A JP2001587559 A JP 2001587559A JP 2004505017 A JP2004505017 A JP 2004505017A
- Authority
- JP
- Japan
- Prior art keywords
- amino
- day
- treatment
- chloroquine
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 45
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 title claims abstract description 30
- 229960003677 chloroquine Drugs 0.000 title claims abstract description 30
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 title claims abstract description 30
- 201000004792 malaria Diseases 0.000 title claims abstract description 28
- -1 (4-((6-methoxy-8-quinolinyl) amino) pentyl) amino Chemical group 0.000 title claims abstract description 11
- 239000003430 antimalarial agent Substances 0.000 claims abstract description 37
- 239000002775 capsule Substances 0.000 claims abstract description 25
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 20
- AEUAEICGCMSYCQ-UHFFFAOYSA-N 4-n-(7-chloroquinolin-1-ium-4-yl)-1-n,1-n-diethylpentane-1,4-diamine;dihydrogen phosphate Chemical compound OP(O)(O)=O.ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 AEUAEICGCMSYCQ-UHFFFAOYSA-N 0.000 claims abstract description 15
- 229960002328 chloroquine phosphate Drugs 0.000 claims abstract description 15
- ADCOUXIGWFEYJP-UHFFFAOYSA-N 3-[1-[4-[(6-methoxyquinolin-8-yl)amino]pentylamino]ethylidene]oxolan-2-one Chemical compound C=12N=CC=CC2=CC(OC)=CC=1NC(C)CCCNC(C)=C1CCOC1=O ADCOUXIGWFEYJP-UHFFFAOYSA-N 0.000 claims abstract description 12
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims abstract description 10
- 239000000463 material Substances 0.000 claims abstract description 5
- 150000001875 compounds Chemical class 0.000 claims description 44
- 206010035503 Plasmodium vivax infection Diseases 0.000 claims description 11
- 201000009976 Plasmodium vivax malaria Diseases 0.000 claims description 11
- 208000005469 Vivax Malaria Diseases 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 9
- 239000003814 drug Substances 0.000 abstract description 19
- 229940079593 drug Drugs 0.000 abstract description 15
- 241000223810 Plasmodium vivax Species 0.000 abstract description 6
- RHDGNLCLDBVESU-UHFFFAOYSA-N but-3-en-4-olide Chemical compound O=C1CC=CO1 RHDGNLCLDBVESU-UHFFFAOYSA-N 0.000 abstract description 3
- 229960005179 primaquine Drugs 0.000 description 34
- INDBQLZJXZLFIT-UHFFFAOYSA-N primaquine Chemical compound N1=CC=CC2=CC(OC)=CC(NC(C)CCCN)=C21 INDBQLZJXZLFIT-UHFFFAOYSA-N 0.000 description 32
- 108010061951 Methemoglobin Proteins 0.000 description 11
- 208000015181 infectious disease Diseases 0.000 description 9
- 231100000419 toxicity Toxicity 0.000 description 9
- 230000001988 toxicity Effects 0.000 description 9
- 230000000694 effects Effects 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 241000282693 Cercopithecidae Species 0.000 description 4
- 238000002648 combination therapy Methods 0.000 description 4
- XEEQGYMUWCZPDN-DOMZBBRYSA-N (-)-(11S,2'R)-erythro-mefloquine Chemical compound C([C@@H]1[C@@H](O)C=2C3=CC=CC(=C3N=C(C=2)C(F)(F)F)C(F)(F)F)CCCN1 XEEQGYMUWCZPDN-DOMZBBRYSA-N 0.000 description 3
- 241000224016 Plasmodium Species 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 230000000078 anti-malarial effect Effects 0.000 description 3
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 3
- 231100001231 less toxic Toxicity 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 229960001962 mefloquine Drugs 0.000 description 3
- 230000000306 recurrent effect Effects 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 102100031126 6-phosphogluconolactonase Human genes 0.000 description 2
- 108010029731 6-phosphogluconolactonase Proteins 0.000 description 2
- OVCDSSHSILBFBN-UHFFFAOYSA-N Amodiaquine Chemical compound C1=C(O)C(CN(CC)CC)=CC(NC=2C3=CC=C(Cl)C=C3N=CC=2)=C1 OVCDSSHSILBFBN-UHFFFAOYSA-N 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000282560 Macaca mulatta Species 0.000 description 2
- 241000223960 Plasmodium falciparum Species 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 229960001444 amodiaquine Drugs 0.000 description 2
- BLUAFEHZUWYNDE-NNWCWBAJSA-N artemisinin Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2OC(=O)[C@@H]4C BLUAFEHZUWYNDE-NNWCWBAJSA-N 0.000 description 2
- 229960004191 artemisinin Drugs 0.000 description 2
- 229930101531 artemisinin Natural products 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000029052 metamorphosis Effects 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- IOTAOYHKWICOBK-UHFFFAOYSA-N 1-[amino-(4-chloroanilino)methylidene]-2-propan-2-ylguanidine;3-[4-(4-chlorophenyl)cyclohexyl]-4-hydroxynaphthalene-1,2-dione;hydrochloride Chemical compound Cl.CC(C)N=C(N)\N=C(/N)NC1=CC=C(Cl)C=C1.O=C1C(=O)C2=CC=CC=C2C(O)=C1C(CC1)CCC1C1=CC=C(Cl)C=C1 IOTAOYHKWICOBK-UHFFFAOYSA-N 0.000 description 1
- YEJRWHAVMIAJKC-UHFFFAOYSA-N 4-Butyrolactone Chemical compound O=C1CCCO1 YEJRWHAVMIAJKC-UHFFFAOYSA-N 0.000 description 1
- HQWQVBJUIIJTRE-LKRNKTNVSA-N 4-amino-n-(5,6-dimethoxypyrimidin-4-yl)benzenesulfonamide;(s)-[2,8-bis(trifluoromethyl)quinolin-4-yl]-[(2r)-piperidin-2-yl]methanol;5-(4-chlorophenyl)-6-ethylpyrimidine-2,4-diamine;hydron;chloride Chemical compound Cl.CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1.COC1=NC=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1OC.C([C@@H]1[C@@H](O)C=2C3=CC=CC(=C3N=C(C=2)C(F)(F)F)C(F)(F)F)CCCN1 HQWQVBJUIIJTRE-LKRNKTNVSA-N 0.000 description 1
- LUBUTTBEBGYNJN-UHFFFAOYSA-N 4-amino-n-(5,6-dimethoxypyrimidin-4-yl)benzenesulfonamide;5-(4-chlorophenyl)-6-ethylpyrimidine-2,4-diamine Chemical compound CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1.COC1=NC=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1OC LUBUTTBEBGYNJN-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010003399 Arthropod bite Diseases 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- 241000552118 Cubana Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- FOHHNHSLJDZUGQ-VWLOTQADSA-N Halofantrine Chemical compound FC(F)(F)C1=CC=C2C([C@@H](O)CCN(CCCC)CCCC)=CC3=C(Cl)C=C(Cl)C=C3C2=C1 FOHHNHSLJDZUGQ-VWLOTQADSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241001505293 Plasmodium ovale Species 0.000 description 1
- PJSFRIWCGOHTNF-UHFFFAOYSA-N Sulphormetoxin Chemical compound COC1=NC=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1OC PJSFRIWCGOHTNF-UHFFFAOYSA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229940033495 antimalarials Drugs 0.000 description 1
- 230000006851 antioxidant defense Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 125000000219 ethylidene group Chemical group [H]C(=[*])C([H])([H])[H] 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 150000002241 furanones Chemical class 0.000 description 1
- 229960003242 halofantrine Drugs 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 229940080435 lactose 250 mg Drugs 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000003936 merozoite Anatomy 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229960005385 proguanil Drugs 0.000 description 1
- SSOLNOMRVKKSON-UHFFFAOYSA-N proguanil Chemical compound CC(C)\N=C(/N)N=C(N)NC1=CC=C(Cl)C=C1 SSOLNOMRVKKSON-UHFFFAOYSA-N 0.000 description 1
- WKSAUQYGYAYLPV-UHFFFAOYSA-N pyrimethamine Chemical compound CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1 WKSAUQYGYAYLPV-UHFFFAOYSA-N 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- ZISJLHQNEVGTIU-RFEYTNPVSA-M sodium 4-oxo-4-[[(1R,4S,5R,8S,9R,10S,12R,13R)-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-yl]oxy]butanoate Chemical compound [Na+].C[C@@H]1CC[C@H]2[C@@H](C)[C@H](OC(=O)CCC([O-])=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4 ZISJLHQNEVGTIU-RFEYTNPVSA-M 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229960004673 sulfadoxine Drugs 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN501MU2000 | 2000-05-31 | ||
| PCT/IN2000/000081 WO2001091535A2 (en) | 2000-05-31 | 2000-08-30 | A combination kit used in the treatment of malaria containing chloroquine and 3-(1-(((4-((6-methoxy-8-quinolinyl)amino)pentyl)amino)-ethylidene)-dihydro-2(3h)furanone enthält |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004505017A true JP2004505017A (ja) | 2004-02-19 |
| JP2004505017A5 JP2004505017A5 (enrdf_load_stackoverflow) | 2007-10-04 |
Family
ID=11097250
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001587559A Pending JP2004505017A (ja) | 2000-05-31 | 2000-08-30 | クロロキンおよび３−（１−（（（４−（（６−メトキシ−８−キノリニル）アミノ）ペンチル）アミノ）−エチリデン）−ジヒドロ−２（３ｈ）フラノンを含有するマラリア治療に使用される組み合わせキット |
Country Status (28)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2642672A1 (en) * | 2006-02-16 | 2007-08-30 | The Mclean Hospital Corporation | Methods and compositions for the treatment of parkinson's disease |
| EP2379505A4 (en) * | 2008-12-05 | 2012-10-17 | Designmedix Inc | CHLOROQUINES MODIFIED BY A MONOCYCLIC GROUP OR A FUSED CYCLE GROUP |
| WO2010144102A1 (en) * | 2009-06-09 | 2010-12-16 | The United States Of America, As Represented By The Secretary Of The Army, On Behalf Of U.S. Army Medical Research And Material Command | Pentafluorosulfanyl analogs of mefloquine |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4431807A (en) * | 1980-06-12 | 1984-02-14 | The United States Of America As Represented By The Secretary Of The Army | 4-Methyl-5-(unsubstituted and substituted phenoxy)-6-methoxy-8-(aminoalkylamino)quinolines |
| US5219865A (en) * | 1987-05-08 | 1993-06-15 | Hoechst Aktiengesellschaft | Pharmaceutical combination for the prophylaxis and therapy of malaria |
| US5373005A (en) * | 1988-04-20 | 1994-12-13 | Merrell Dow Pharmaceuticals Inc. | Despiramine in the treatment of drug-resistant malarial infections |
| US5270037A (en) * | 1990-07-12 | 1993-12-14 | Boehringer Ingelheim Gmbh | Use of interferon and a substance with an antimalarial activity for the treatment of malaria infections |
| FI934360A0 (fi) * | 1992-02-07 | 1993-10-04 | Ciba Geigy Ag | Synergistiska antimalariakompositioner innehaollande benflumetol |
-
2000
- 2000-08-30 WO PCT/IN2000/000081 patent/WO2001091535A2/en active IP Right Grant
- 2000-08-30 HU HU0301925A patent/HUP0301925A3/hu unknown
- 2000-08-30 AU AU2001228790A patent/AU2001228790B2/en not_active Ceased
- 2000-08-30 DE DE0001292306T patent/DE00993875T1/de active Pending
- 2000-08-30 KR KR1020027016169A patent/KR20030025926A/ko not_active Ceased
- 2000-08-30 OA OA1200200359A patent/OA12276A/en unknown
- 2000-08-30 ES ES00993875T patent/ES2200729T3/es not_active Expired - Lifetime
- 2000-08-30 MX MXPA02011883A patent/MXPA02011883A/es active IP Right Grant
- 2000-08-30 DK DK00993875T patent/DK1292306T3/da active
- 2000-08-30 US US10/296,215 patent/US7404962B1/en not_active Expired - Fee Related
- 2000-08-30 DE DE60025403T patent/DE60025403T2/de not_active Expired - Lifetime
- 2000-08-30 EP EP00993875A patent/EP1292306B1/en not_active Expired - Lifetime
- 2000-08-30 HK HK03104811.6A patent/HK1052467B/en not_active IP Right Cessation
- 2000-08-30 PL PL372718A patent/PL200748B1/pl not_active IP Right Cessation
- 2000-08-30 CZ CZ20024071A patent/CZ296875B6/cs not_active IP Right Cessation
- 2000-08-30 JP JP2001587559A patent/JP2004505017A/ja active Pending
- 2000-08-30 CA CA002413775A patent/CA2413775C/en not_active Expired - Fee Related
- 2000-08-30 AU AU2879001A patent/AU2879001A/xx active Pending
- 2000-08-30 AP APAP/P/2002/002672A patent/AP1435A/en active
- 2000-08-30 AT AT00993875T patent/ATE314848T1/de active
- 2000-10-05 EC EC2000003694A patent/ECSP003694A/es unknown
- 2000-10-13 SV SV2000000201A patent/SV2002000201A/es unknown
- 2000-10-25 GT GT200000187A patent/GT200000187A/es unknown
- 2000-11-06 BR BR0005247-7A patent/BR0005247A/pt not_active Application Discontinuation
-
2001
- 2001-05-14 AR ARP010102288A patent/AR028458A1/es unknown
- 2001-05-23 PE PE2001000469A patent/PE20011319A1/es not_active Application Discontinuation
- 2001-05-30 HN HN2001000118A patent/HN2001000118A/es unknown
-
2002
- 2002-11-28 CR CR6835A patent/CR6835A/es not_active Application Discontinuation
- 2002-11-29 NO NO20025765A patent/NO324774B1/no not_active IP Right Cessation
- 2002-11-29 ZA ZA200209726A patent/ZA200209726B/en unknown
Non-Patent Citations (9)
| Title |
|---|
| JPN5002025983, ＫＡＲ，Ｋ．, ＩＮＤＩＡＮ Ｊ．ＰＡＲＡＳＩＴＯＬ．, 1988, Ｖ１２, Ｐ２５９−２６２ * |
| JPN5002025984, ＤＵＴＴＡ，Ｇ．Ｐ．, ＡＭ．Ｊ．ＴＲＯＰ．ＭＥＤ．ＨＹＧ．, 1989, Ｖ４１ Ｎ６, Ｐ６３５−６３７ * |
| JPN5002025985, ＰＵＲＩ，Ｓ．Ｋ．, ＡＭ．Ｊ．ＴＲＯＰ．ＭＥＤ．ＨＹＧ．, 1989, Ｖ４１ Ｎ６, Ｐ６３８−６４２ * |
| JPN5002025986, ＳＥＴＨＩ，Ｎ．, ＩＮＤＩＡＮ Ｊ．ＰＡＲＡＳＩＴＯＬ．, 1993, Ｖ１７ Ｎ１, Ｐ１５−２６ * |
| JPN5002025987, ＰＡＬＩＷＡＬ，ＪＹＯＴＩ ＫＵＭＡＲ, Ｊ．ＣＨＲＯＭＡＴＯＧＲ．，ＢＩＯＭＥＤ．ＡＰＰＬ．, 1993, Ｖ６１６ Ｎ１, Ｐ１５５−１６０ * |
| JPN5002025988, ＮＥＷＴＯＮ Ｐ．, ＡＮＮＵＡＬ ＲＥＶＩＥＷ ＯＦ ＭＥＤＩＣＩＮＥ, 1999, Ｖ５０, Ｐ１７９−１９２ * |
| JPN5002025989, ＢＥＬＬ Ａ．, ＣＵＲＲＥＮＴ ＯＰＩＮＩＯＮ ＩＮ ＡＮＴＩ−ＩＮＦＥＣＴＩＶＥ ＩＮＶＥＳＴＩＧＡＴＩＯＮＡＬ ＤＲＵＧＳ, 2000, Ｖ２ Ｎ１, Ｐ６３−７０ * |
| JPN6010066677, メルクマニュアル, 19950501, 第１６版, ｐｐ． ２２５−２２６ * |
| JPN6010066678, Ｍａｒｋ Ｒｏｗｌａｎｄ ｅｔ ａｌ．, "Ｒａｎｄｏｍｉｚｅｄ ｃｏｎｔｒｏｌｌｅｄ ｔｒｉａｌｓ ｏｆ ５− ａｎｄ １４−ｄａｙｓ ｐｒｉｍａｑｕｉｎｅ ｔｈｅｒａｐｙ ａｇａｉｎｓｔ ｒｅｌａｐｓｅｓ ｏｆ ｖｉｖａｘ ｍａｌａｒｉａ", Ｔｒａｎｓａｃｔｉｏｎｓ ｏｆ ｔｈｅ Ｒｏｙａｌ Ｓｏｃｉｅｔｙ ｏｆ Ｔｒｏｐｉｃａｌ Ｍｅｄｉｃｉｎｅ ａｎｄ Ｈｙｇｉｅｎｅ, 1999, Ｖｏｌ． ９３， Ｎｏ． ６, ｐｐ． ６４１−６４３ * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Iseman et al. | Drug-resistant tuberculosis | |
| Davis et al. | Artemisinin‐based combination therapies for uncomplicated malaria | |
| AU2021202235B2 (en) | Therapeutic regimen of 2-amino-l-(2-(4-fluorophenyl)-3-(4-fluorophenylamino)-8,8-dimethyl-5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)ethanone and combinations thereof | |
| AU614515B2 (en) | A pharmaceutical combination for the prophylaxis and therapy of malaria | |
| WO2005023304A2 (en) | Antimalarial compositions and manufacturing process thereof | |
| JP2004520374A (ja) | 血圧降下剤としてのカロテノイド | |
| JP2004505017A (ja) | クロロキンおよび３−（１−（（（４−（（６−メトキシ−８−キノリニル）アミノ）ペンチル）アミノ）−エチリデン）−ジヒドロ−２（３ｈ）フラノンを含有するマラリア治療に使用される組み合わせキット | |
| Krudsood et al. | Dose ranging studies of new artemisinin-piperaquine fixed combinations compared to standard regimens of artemisisnin combination therapies for acute uncomplicated falciparum malaria | |
| KR20140053169A (ko) | 아르테롤란 및 피페라퀸의 안정한 제형 | |
| EP0214933A2 (de) | Kombinationspräparate zur Behandlung von Malaria | |
| EP1476160B1 (en) | Pharmaceutical combination of artesunate and mefloquine for therapy of malaria | |
| JP2001507672A (ja) | Ｃｉｓ―縮合シクロペンテノ―１，２，４―トリオキサン誘導体を含有する抗マラリア組成物 | |
| JP3560970B2 (ja) | ベンゾフルメトールを含有する抗マラリア性の相乗作用組成物 | |
| JPH11513365A (ja) | １，２，４−ベンゾトリアジンオキシドの経口ゲルカプセル製剤 | |
| US20220265644A1 (en) | Fixed dose combination drug for the treatment of malaria | |
| Pacifici | Clinical Pharmacology of the Antimalarial Proguanil in Infants and Children | |
| US20180042857A1 (en) | Soft gelatin capsules containing fexofenadine | |
| Rezeki et al. | Severe Vivax Malaria Infection in Infants: Case Report | |
| WO2022049548A1 (en) | Kaf156 combinations and methods for the treatment of malaria | |
| JPH04230322A (ja) | 抗マラリア医薬組成物 | |
| OA21170A (en) | Fixed dose combination drug for the treatment of malaria. | |
| Brampton | PrRAN™-SILDENAFIL | |
| Song et al. | Current Treatments for Malaria 10 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070731 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070731 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20101130 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110222 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110301 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110330 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20111108 |